Transcribed Ultraconserved Region (T-UCR) Uc.261 Expression is Closely Correlated with Disease Activity and Intestinal Permeability in Crohn's Disease

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2019 Oct 31

PMID 31662792

Citations 4

Authors

Xiao-Xian Qian

Chen-Wen Cai

Han-Yang Li

Li-Jie Lai

Dong-Juan Song

Yu-Qi Qiao

Jun Shen

Zhi-Hua Ran

Affiliations

Soon will be listed here.

Abstract

Objectives: Transcribed ultraconserved region (T-UCR) uc.261 is reported to participate in intestinal mucosa barrier damage in Crohn's disease (CD). The aim of this study was to determine the association with disease activity and intestinal permeability.

Methods: Uc.261 level in colon mucosa and Harvey-Bradshaw Index (HBI) were evaluated in 20 active CD patients. Uc.261 expression and transepithelial electrical resistance (TEER) were determined in Caco2 and T84 cells treated with tumor necrosis factor alpha (TNF-α), respectively. Body weight, disease activity index (DAI), colon length, histological index (HI), intestinal permeability to FITC-dextran, uc.261, and tight junction proteins (TJPs) levels were evaluated in BALB/C mice treated with saline enema, trinitrobenzene sulfonic acid (TNBS)/ethanol enema, and anti-TNF-α monoclonal antibody injection, respectively.

Results: Uc.261 expression was overexpressed in CD patients, TNF-α treated cells, and colitis mice. Uc.261 expression was positively correlated with HBI ( = 0.582, = 0.007) in CD patients, and positively correlated with TNF-α concentration and negatively correlated TEER in Caco2 and T84 cells (all < 0.05). Furthermore, uc.261 was positively correlated with DAI ( = 0.824, = 0.008), HI ( = 0.672, = 0.021), and intestinal permeability ( = 0.636, = 0.012), while negatively correlated with body weight ( = -0.574, = 0.035), colon length ( = -0.866, = 0.017), and TJP expression (all < 0.05) in colitis mice.

Conclusions: Uc.261 expression was closely correlated with disease activity and intestinal permeability in CD. Anti-TNF-α treatment may play its role through suppressing uc.261 expression in colitis mice.

Citing Articles

Bifidobacterium longum SX-1326 ameliorates gastrointestinal toxicity after irinotecan chemotherapy via modulating the P53 signaling pathway and brain-gut axis.

Yue F, Zeng X, Wang Y, Fang Y, Yue M, Zhao X BMC Microbiol. 2024; 24(1):8.

PMID: 38172689 PMC: 10763180. DOI: 10.1186/s12866-023-03152-w.

Ultra-conserved RNA: a novel biological tool with diagnostic and therapeutic potential.

Wang T, Li F, Lu Z Discov Oncol. 2023; 14(1):41.

PMID: 37036543 PMC: 10086085. DOI: 10.1007/s12672-023-00650-1.

Pulsatilla decoction alleviates colitis by enhancing autophagy and regulating PI3K‑Akt‑mTORC1 signaling pathway.

Wang X, Xu L, Wang T, Xu J, Fan F, Zhang Y Mol Med Rep. 2022; 25(3).

PMID: 35103289 PMC: 8822884. DOI: 10.3892/mmr.2022.12624.

Overexpression of the transcribed ultraconserved region Uc.138 accelerates colon cancer progression.

Kuwano Y, Nishida K, Rokutan K Sci Rep. 2021; 11(1):8667.

PMID: 33883665 PMC: 8060298. DOI: 10.1038/s41598-021-88123-9.

References

Reimund J, Dumont S, Muller C, KENNEY J, Kedinger M, Baumann R . In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut. 1997; 40(4):475-80. PMC: 1027121. DOI: 10.1136/gut.40.4.475. View

Kiss L, Papp M, Lovasz B, Vegh Z, Golovics P, Janka E . High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?. Inflamm Bowel Dis. 2011; 18(9):1647-54. DOI: 10.1002/ibd.21933. View

Maerten P, Shen C, Colpaert S, Liu Z, Bullens D, Van Assche G . Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol. 2004; 135(2):310-7. PMC: 1808939. DOI: 10.1111/j.1365-2249.2004.02362.x. View

Gerova V, Stoynov S, Katsarov D, Svinarov D . Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. World J Gastroenterol. 2011; 17(17):2211-5. PMC: 3092873. DOI: 10.3748/wjg.v17.i17.. View

Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss H, Bentzel C . Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999; 116(2):301-9. DOI: 10.1016/s0016-5085(99)70126-5. View

Chen P, Kartha S, Bissonnette M, Hart J, Toback F . AMP-18 facilitates assembly and stabilization of tight junctions to protect the colonic mucosal barrier. Inflamm Bowel Dis. 2012; 18(9):1749-59. PMC: 3337967. DOI: 10.1002/ibd.22886. View

Daperno M, DHaens G, Van Assche G, Baert F, Bulois P, Maunoury V . Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60(4):505-12. DOI: 10.1016/s0016-5107(04)01878-4. View

Peterson T, Davey K . Effect of acute pentoxifylline treatment in an experimental model of colitis. Aliment Pharmacol Ther. 1997; 11(3):575-80. DOI: 10.1046/j.1365-2036.1997.00188.x. View

Chang J, Leong R, Wasinger V, Ip M, Yang M, Phan T . Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. Gastroenterology. 2017; 153(3):723-731.e1. DOI: 10.1053/j.gastro.2017.05.056. View

10.

Irvine E, Marshall J . Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology. 2000; 119(6):1740-4. DOI: 10.1053/gast.2000.20231. View

11.

Fukui H . Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?. Inflamm Intest Dis. 2018; 1(3):135-145. PMC: 5988153. DOI: 10.1159/000447252. View

12.

DInca R, Di Leo V, Corrao G, Martines D, DOdorico A, Mestriner C . Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol. 1999; 94(10):2956-60. DOI: 10.1111/j.1572-0241.1999.01444.x. View

13.

Bejerano G, Pheasant M, Makunin I, Stephen S, Kent W, Mattick J . Ultraconserved elements in the human genome. Science. 2004; 304(5675):1321-5. DOI: 10.1126/science.1098119. View

14.

Wirtz S, Neufert C, Weigmann B, Neurath M . Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2(3):541-6. DOI: 10.1038/nprot.2007.41. View

15.

Vermeire S, Schreiber S, Sandborn W, Dubois C, Rutgeerts P . Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010; 8(4):357-63. DOI: 10.1016/j.cgh.2010.01.001. View

16.

Oshitani N, Watanabe K, Nakamura S, Fujiwara Y, Higuchi K, Arakawa T . Dislocation of tight junction proteins without F-actin disruption in inactive Crohn's disease. Int J Mol Med. 2005; 15(3):407-10. View

17.

Williams C, Bradley A, Chaturvedi R, Singh K, Piazuelo M, Chen X . MTG16 contributes to colonic epithelial integrity in experimental colitis. Gut. 2012; 62(10):1446-55. PMC: 3663894. DOI: 10.1136/gutjnl-2011-301439. View

18.

Volynets V, Reichold A, Bardos G, Rings A, Bleich A, Bischoff S . Assessment of the Intestinal Barrier with Five Different Permeability Tests in Healthy C57BL/6J and BALB/cJ Mice. Dig Dis Sci. 2015; 61(3):737-46. DOI: 10.1007/s10620-015-3935-y. View

19.

Shen C, De Hertogh G, Bullens D, Van Assche G, Geboes K, Rutgeerts P . Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization?. Inflamm Bowel Dis. 2007; 13(3):308-16. DOI: 10.1002/ibd.20005. View

20.

Qiao Y, Huang M, Xu A, Zhao D, Ran Z, Shen J . LncRNA DQ786243 affects Treg related CREB and Foxp3 expression in Crohn's disease. J Biomed Sci. 2013; 20:87. PMC: 4174896. DOI: 10.1186/1423-0127-20-87. View